108 results about "Amphomycin" patented technology

The invention which belongs to the biotechnical field concretely relates to a brain targeted AmB polymer micelle administration system. The brain targeted AmB polymer micelle administration system is prepared by utilizing brain targeted head base Angiopep-2 modified polymer micelles extremely having a clinical application potential, and entrapping micromolecular hydrophobic drugs. The prepared brain targeted AmB polymer micelle administration system can effectively improve the uptaking of the hydrophobic drugs on brain capillary endothelial cells, and can effectively improve the accumulation amount of the drugs in the brain and the brain entrance efficiency of the drugs especially in a noninvasive intravenous injection mode; compared with present clinical preparations of the drugs, such as AmB for injection, the system of the invention has a substantially improved brain targeting efficiency; and the constructed polymer micelle administration system can obviously reduce the hemolyticity and the cytotoxicity of the AmB. The Angiopep-2 modified brain targeted AmB polymer micelle administration system of the invention can be used to promote the accumulation of hydrophobic drugs with low brain entrance efficiencies in the brain.

The invention discloses a tissue sample preservative solution used for preserving tissue samples, such as fat, umbilical cords, placentas and the like, after collection and before separation. The tissue sample preservative solution mainly comprises following components: high-glucose DMEM dry-powder culture medium, sodium bicarbonate, DMSO, dexamethasone, insulin, penicillin, streptomycin, amphotericin and a heparin sodium injection. The high-glucose DMEM dry-powder culture medium and the sodium bicarbonate are used for maintaining osmotic equilibrium among cells inside and outside tissue, maintaining a pH value, maintaining a moistening situation of the tissue and providing nutritional components. The DMSO is a freeze-storage protective agent and can prevent freeze-injuries on the tissue samples. The dexamethasone can inhibit immunization and protect activity of stem cells in the tissue sample; the insulin can promote absorption and utilization of the tissue sample to glucose. The penicillin, the streptomycin and the amphotericin can prevent pollution from bacteria and moulds and can eliminate pollution which has occurred. The heparin sodium injection can prevent blood solidification in the tissue samples and increase a yield of the stem cells. The tissue sample preservative solution is simple in components, is low in cost, is convenient to use, can maintain activities of the stem cells in the tissue samples, such as fat, umbilical cords, placentas and the like, and can greatly reduce a time limit from collection to preparation of the tissue samples.

The invention relates to application of an effective part of a cockroach extract in preparing a drug for inhibiting fungus growth, and particularly relates to application of an effective part obtained by refining a crude cockroach extract through macroporous adsorption resin in the aspect of preparing a drug capable of resisting fungal infection. The effective part is refined from a fresh or dried Periplaneta americana L. polypide product through alcohol and water extraction, macroporous adsorption resin column chromatography and alcohol solvent elution, and has an obvious inhibition effect on the growth activity of candida albicans and a fungus growth inhibition capacity 80 times higher than that of fluconazole and 5-fluorocytosine and 800 times higher than that of amphotericin. The effective part of the cockroach extract can be prepared into forms, such as a hydrogel, a frothy gel, a cataplasm, freeze-dried powder, a water aqua, an aerosol, a suppository, a film, an external liniment, an ointment and the like, and is used for preparing pharmaceutical preparations for preventing and curing fungal infection, medical appliances and daily-use chemical products.

The invention provides a preserving fluid for preserving a virus sample at normal temperature for a long time. The preserving fluid is equipped whit nutrient substances such as salts, amino acids, glucose and the like required by virus survival, is added with virus protective agents such as polyvinylpyrrolidone, mannitol, trehalose and the like for protecting viruses, and is added with bacteriostatic agents such as amphotericin B, vancomycin and the like for inhibiting the growth of bacteria. The preserving fluid is safe and non-toxic, is simple to use, does not need cold chain preservation, can be used for transporting and preserving the virus sample at normal temperature for 3 days, and effectively solves the problems that the virus samples depend on cold chains in the sampling, transporting and preserving processes and the preservation time is short. The preserving fluid can maintain the primitiveness of the virus sample, is beneficial to comprehensive analysis and research of the virus sample, and is suitable for collection and transportation of epidemic virus samples.

The invention relates to genitourinary tract microorganism cultivation and detect method thereof, in particular to a genitourinary tract ureaplasma urealyticum (Uu) and mycoplasma hominis (Mh) culture medium and a detect method thereof. The culture medium comprises a fluid medium and a solid medium which are combined when the medium is used for culturing, separating and differentiating mycoplasma. The formulation comprises essential elements such as tryptic soy broth, yeast extract, urea, arginine, L-cysteine, phenol red, HEPES liquid, calf (fetal calf) serum, manganese sulfate, vancomycin, amphotericin B, trimethoprim, polymyxin, penicillin, and the like, and thereby the nutrition for mycoplasma growth and the antibiotic combination for inhibiting undesired microbe growth are optimized, no millipore filter is needed for sample inoculation and subcultivation, and the mycoplasma grows quickly. The fluid medium can maintain and prolong the logarithmic phase and indicate the growth of the mycoplasma, and the solid medium can used for observing Uu and Mh bacterial colonies, which has large background reflectance, thereby being easy for differentiation and significantly increasing the sensibility and the specificity of genitourinary tract mycoplasma detect.

The invention discloses a novel rare earth-silver nanocluster antibacterial agent and a preparation method thereof. According to the invention, rare earth and silver elements with antibacterial properties are combined together to form the rare earth-containing silver nanocluster. A novel rare earth-silver nanocluster antibacterial agent is developed by utilizing the synergistic effect of the rare earth and silver elements. The antibacterial agent is a microcrystalline product, the microstructure of the antibacterial agent is analyzed by an X single crystal diffractometer, and a certain contribution can be made to the research of the structure-activity relationship of the rare earth element antibacterial mechanism. The inhibition zone method test shows that the antibacterial property of the nanocluster on common bacteria and fungi is equivalent to that of a common antibacterial agent gentamycin/amphotericin. The prepared rare earth-silver nanocluster antibacterial agent can be applied to various fields of antibacterial macromolecules, antibacterial coatings, antibacterial fabrics and the like, and then is used for manufacturing ceramic bathroom accessories, fresh air systems, indoor decoration coatings, clothes and other products.

The invention provides a drug for inhibiting enterovirus 71. Amphotericin B for clinically treating fungal infection is found to have the characteristic of inhibiting enterovirus 71; through a drug toxicity test, an inhibition test of the drug to viruses and a virus plaque formation test, the amphotericin B is found to obviously inhibit infection of the EV71 virus in an RD cell and a 293 cell; furthermore, the amphotericin B is found to play the virus infection resistance through influencing the adsorption of the EV71 virus. The drug provided by the invention is a novel drug for preventing and treating the enterovirus 71, and is higher in market value and good in clinical application prospect.

The invention discloses a targeted drug composition for co-loading amphotericin B and adriamycin and an application of the targeted drug composition, and belongs to the fields of medicines and pharmaceutics, and provides a novel medical composition for treating leishmaniasis. Two medicines of amphotericin B and adriamycin having fluorescent tracing properties are used and loaded in a pharmaceutical carrier material which is favorable in biological safety and has pH responsiveness to form the medical composition, wherein the carrier material consists of hydrophilicity mannose residues which actively target macrophages, beta-cyclodextrin and hydrophobic propionyl. The medical composition is good in biological safety (cytotoxicity and hemolytic activity), and the stability, pH response medicine release properties, target capacity, and treatment efficiency are verified in a cell model. Besides, the synergistic reaction of the amphotericin B and the adriamycin is realized, so that the consumption of the medicine is greatly reduced, the side effect is reduced, the economic burden of patients is alleviated, and the targeted drug composition is hopeful to exert great effects on clinical application.

The invention discloses an application of a kind of small molecule compounds as an adjuvant in the preparation of antifungal drugs. After 51,520 small molecule compounds in a national compound sample bank are subjected to high-throughput screening, the result shows that when small molecule compounds as shown in a formula I to a formula X independently act on a candida albicans biological membrane, the inhibition ratio is almost zero, but when the small molecule compounds are used with conventional antifungal drugs such as amphotericin B, fluconazole or caspofungin, the remarkable synergism is achieved, the efficacy of the conventional antifungal drugs is improved by 30% or above, the use dosage of the conventional antifungal drugs is reduced, and the inhibiting effect of the antifungal drugs to drug resistance fungi is improved.

The present invention provides two new classes of polyene macrolide amide derivatives useful for treating or preventing fungal infections. The new polyene macrolide amide derivatives exhibit antifungal activity and are more water-soluble than conventional polyene antibiotics, such as amphotericin B and amphotericin B methyl ester.

The invention provides a high-throughput screening method for anti-breast cancer drugs. The method is different from previous methods, and can provide accurate individualized treatment selection for cancer patients. The concentrations of amphotericin B and gentamicin in a tumor cell culture solution are controlled to improve the survival rate of tumor cells, effectively maintain the cell morphology and promote the absorption of nutrients by the tumor cells. The concentrations of insulin and a growth factor EGF in the tumor cell culture solution are controlled to improve the growth rate of thetumor cells and improve the cell activity, so a large number of highly active tumor cells can be obtained; and certain proportions of the insulin and the growth factor can be used to reduce the use amount of fetal calf serum, the fetal calf serum has a high price, so the reduction of the use amount facilitates resource saving; and the half-inhibitory concentration (IC50) error of the drug determined through drug screening using the cultured cells is small, so the detection frequency can be reduced.

The invention discloses a pharmaceutical composition capable of killing drug-resistant aspergillus fumigatus and a method for killing drug-resistant aspergillus fumigatus, and belongs to the technical field of microorganism. The pharmaceutical composition is prepared from citral and an antifungal drug, wherein the antifungal drug comprises amphotericin B, voriconazole and itraconazole. The method for killing drug-resistant aspergillus fumigatus comprises the steps of preparing the composition, preparing a spore suspension, determining the drug MIC (Minimal Inhibitory Concentration) and carrying out a united drug sensitivity test. The pharmaceutical composition disclosed by the invention improves the antibacterial effect of the drug to the drug-resistant strain, reduces the toxic or side effects of the antifungal drug and is an ideal pharmaceutical composition for treating antifungal drug resistant aspergillus fumigatus infection.

The invention discloses a culture medium for helicobacter pylori as well as a preparation method and application of the culture medium, and belongs to the technical field of microorganisms. Specifically, the invention provides the culture medium for the helicobacter pylori, and every 1000 mL of the culture medium for the helicobacter pylori contains 3 to 10 g of agar, 5 to 10 g of cysteine, 0.3 to 0.8 mg of antibiotics, 3 to 10 g of soluble starch, 0.1 to 1 mL of lactic acid and 1 to 10 g of horse whole blood. Wherein the antibiotics are prepared from vancomycin, amphotericin B and polymyxin; in the antibiotics, the mass fraction of vancomycin is 30-60%, the mass fraction of amphotericin B is 30-60%, and the mass fraction of polymyxin is 30-60%. 30% to 80% of amphotericin B; and 0.1%-10% of polymyxin. The invention also provides a preparation method and application of the culture medium. The culture medium provided by the invention is suitable for quick growth and culture of helicobacter pylori, can effectively inhibit the growth of infectious microbes, reduces the use of antibiotics, and has great use value.